EVALUATION OF ANTI-DIABETIC POTENTIAL OF ERYTHROXYLON MONOGYNUMIN STREPTOZOTOCIN INDUCED DIABETIC RATS

Objective: Evaluation of anti-diabetic potential of Erythroxylon monogynum in streptozotocin induced diabetic rats Methods: Diabetes was induced by single dose of steptozotocin (65 mg/kg body weight i.p.) to female wistar rats. Diabetic rats were stabilized for six day and from seventh day chloroform fraction of Erythroxylon monogynum (CEM) was administered at a dose of 250 mg/kg, p.o. and 500 mg/kg for 3 weeks. Glibenclamide 10 mg/kg P.O. was used as a standard. The effect of CEM and standard drug on following parameters were recorded - body weight, blood glucose and various biochemical parameters like serum lipid profile eg. total cholesterol (TC) and triglyceride (TG), HDL-C, LDL-C and VLDL. At the end of the study oxidative stress markers like CAT, GSH and lipid peroxidation were analyzed in the pancreases. Histopathalogical changes were studied in pancreases of representative animals of the each group. Results: Administration of chloroform fraction of Erythroxylon monogynum (CEM) at a dose of 250 mg/kg, p.o. and 500 mg/kg, p.o did not showed any significant change in blood glucose level of normoglycemic rats , whereas, oral glucose tolerance test depicted significant reduction in blood glucose level at 30 (P<0.001)to 60 (P<0.01) min. In streptozotocin induced diabetic rats, CEM was found significantly beneficial in controlling elevated blood glucose level and serum lipid parameters. The findings were strengthening by improved antioxidant status in diabetic rats as well as protection towards pathological damage of pancreases.The results showed by 500 mg/kg of chloroform fraction of Erythroxylon monogynum were comparable with standard treatment of Glibenclamide 10 mg/kg. Conclusion:- Chloroform fraction of Erythroxylon monogynum posses anti-diabetic action in streptozotocin induced diabetic rats.